Canel M, Taggart D, Sims A, Lonergan D, Waizenegger I, Serrels A. T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity. elife. 2020;9: pubmed publisher

Tkachev V, Goodell S, Opipari A, Hao L, Franchi L, Glick G, et al. Programmed death-1 controls T cell survival by regulating oxidative metabolism. J Immunol. 2015;194:5789-800 pubmed publisher

McKay J, Egan R, Yammani R, Chen L, Shin T, Yagita H, et al. PD-1 suppresses protective immunity to Streptococcus pneumoniae through a B cell-intrinsic mechanism. J Immunol. 2015;194:2289-99 pubmed publisher

Jaworska K, Ratajczak J, Huang L, Whalen K, Yang M, Stevens B, et al. Both PD-1 ligands protect the kidney from ischemia reperfusion injury. J Immunol. 2015;194:325-33 pubmed publisher

Erickson J, Rogers M, Hastings A, Tollefson S, Williams J. Programmed death-1 impairs secondary effector lung CD8⁺ T cells during respiratory virus reinfection. J Immunol. 2014;193:5108-17 pubmed publisher

Jensen K, Hu K, Whitmarsh R, Hassan M, Julien L, Lu D, et al. Toxoplasma gondii rhoptry 16 kinase promotes host resistance to oral infection and intestinal inflammation only in the context of the dense granule protein GRA15. Infect Immun. 2013;81:2156-67 pubmed publisher

Van Der Werf N, Redpath S, Azuma M, Yagita H, Taylor M. Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection. PLoS Pathog. 2013;9:e1003215 pubmed publisher

Hafalla J, Claser C, Couper K, Grau G, Renia L, de Souza J, et al. The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology. PLoS Pathog. 2012;8:e1002504 pubmed publisher

Huber S, Hoffmann R, Muskens F, Voehringer D. Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2. Blood. 2010;116:3311-20 pubmed publisher